ATE330585T2 - Behandlung von atemerkrankungen - Google Patents

Behandlung von atemerkrankungen Download PDF

Info

Publication number
ATE330585T2
ATE330585T2 AT01966751T AT01966751T ATE330585T2 AT E330585 T2 ATE330585 T2 AT E330585T2 AT 01966751 T AT01966751 T AT 01966751T AT 01966751 T AT01966751 T AT 01966751T AT E330585 T2 ATE330585 T2 AT E330585T2
Authority
AT
Austria
Prior art keywords
treatment
respiratory diseases
glycopyrrolate
dry powder
formulation
Prior art date
Application number
AT01966751T
Other languages
English (en)
Inventor
Robin Mark Bannister
Andrew John Richards
Julian Clive Gilbert
David A Morton
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE330585(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arakis Ltd filed Critical Arakis Ltd
Application granted granted Critical
Publication of ATE330585T2 publication Critical patent/ATE330585T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
AT01966751T 2000-04-07 2001-04-09 Behandlung von atemerkrankungen ATE330585T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
ATE330585T2 true ATE330585T2 (de) 2006-07-15

Family

ID=9889490

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966751T ATE330585T2 (de) 2000-04-07 2001-04-09 Behandlung von atemerkrankungen

Country Status (25)

Country Link
US (3) US7229607B2 (de)
EP (3) EP1267866B2 (de)
JP (1) JP5042426B2 (de)
CN (3) CN1292745C (de)
AT (1) ATE330585T2 (de)
AU (2) AU2004242450B2 (de)
BE (1) BE2013C023I2 (de)
BR (1) BR0109875A (de)
CA (1) CA2405705C (de)
CY (1) CY1105120T1 (de)
DE (1) DE60120936T3 (de)
DK (1) DK1267866T4 (de)
ES (2) ES2266242T5 (de)
GB (1) GB0008660D0 (de)
HK (1) HK1050846B (de)
HU (2) HU230958B1 (de)
IL (2) IL151791A0 (de)
LU (2) LU92166I2 (de)
MX (1) MXPA02009718A (de)
NO (3) NO336142B1 (de)
NZ (2) NZ535284A (de)
PL (1) PL364024A1 (de)
PT (1) PT1267866E (de)
WO (1) WO2001076575A2 (de)
ZA (1) ZA200207420B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PT1337239E (pt) 2000-11-30 2010-01-26 Vectura Ltd Partículas servindo à preparação de uma composição farmacêutica
PT2283818T (pt) 2000-11-30 2017-10-09 Vectura Ltd Método de preparação de partículas para utilização numa composição farmacêutica
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
DK3384931T3 (da) * 2002-03-01 2019-09-16 Chiesi Farm Spa Superfin formoterolformulering
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7419801B2 (en) * 2003-08-08 2008-09-02 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
DK1684719T3 (da) * 2003-11-14 2012-01-30 Baxter Int Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger
CA2550841C (en) 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
WO2005074983A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
HRP20120286T1 (hr) * 2004-02-06 2012-04-30 Meda Pharma Gmbh & Co. Kg Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
PL1713473T3 (pl) * 2004-02-06 2013-08-30 Meda Pharma Gmbh & Co Kg Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
JP2007524698A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
CA2559062A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006003078A1 (en) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (de) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medikamente enthaltend PDE-IV Hemmer und Glycopyrrolatsalzen zur Inhalation
EP1789018A1 (de) 2004-08-27 2007-05-30 The Dow Chemical Company Verbesserte abgabe von medikamentenzusammensetzungen zur behandlung lebensbedrohender infektionen
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
JP4991693B2 (ja) 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
EP1978933A2 (de) * 2005-12-15 2008-10-15 Acusphere, Inc. Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur oralen verabreichung
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CN101896162B (zh) * 2007-12-13 2013-06-05 诺瓦提斯公司 有机化合物
JP2011506400A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 有機化合物
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2009134524A2 (en) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
LT3578169T (lt) 2009-02-26 2024-08-26 Glaxo Group Limited Farmaciniai preparatai, apimantys 4-{(1r)-2-[(6-{2-[(2,6-dichlorbenzil) oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenolį
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP3111926B1 (de) 2009-05-29 2019-12-11 Pearl Therapeutics, Inc. Zusammensetzungen, verfahren und systeme für die respiratorische verabreichung von zwei oder mehr wirkstoffen
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
UA106098C2 (uk) 2009-12-23 2014-07-25 К'Єзі Фармачеутічі С.П.А. Аерозольна композиція для хозл
CN102695496B (zh) 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
CA2785321C (en) 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
BR112012015334A2 (pt) 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
WO2012044736A1 (en) * 2010-09-29 2012-04-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
ES2708218T3 (es) 2011-08-01 2019-04-09 Univ Monash Método y formulación para inhalación
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
RU2696582C2 (ru) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Способы и системы кондиционирования дисперсных кристаллических материалов
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015094927A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
HUE039513T2 (hu) 2013-12-30 2019-01-28 Chiesi Farm Spa Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény
NZ728435A (en) 2014-09-09 2017-11-24 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
EP3332767B1 (de) * 2014-09-15 2019-03-20 Verona Pharma PLC Flüssige inhalationsformulierung mit rpl554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
AU2016279798B2 (en) * 2015-06-15 2021-07-08 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
PE20221439A1 (es) 2019-12-02 2022-09-21 Chiesi Farm Spa Lata de acero inoxidable para inhaladores dosificadores presurizados

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
PT1371645E (pt) 1996-11-11 2013-05-21 Meda Pharma Gmbh & Co Kg Utilização de (3s,2¿r)-glicopirrónio como produto farmacêutico
ATE287257T1 (de) * 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
AU748867B2 (en) * 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
EP1131059B1 (de) * 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU7389300A (en) * 1999-08-02 2001-02-19 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 漢高智慧財產控股公司 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
EP1267866B1 (de) 2006-06-21
AU776913B2 (en) 2004-09-23
CY1105120T1 (el) 2010-03-03
US8029768B2 (en) 2011-10-04
NZ535284A (en) 2006-04-28
US20030068280A1 (en) 2003-04-10
EP1267866A2 (de) 2003-01-02
EP1449528A1 (de) 2004-08-25
GB0008660D0 (en) 2000-05-31
US20050019271A1 (en) 2005-01-27
CN101181263A (zh) 2008-05-21
JP5042426B2 (ja) 2012-10-03
US7229607B2 (en) 2007-06-12
NO336142B1 (no) 2015-05-26
NZ521476A (en) 2004-10-29
NO2015024I1 (no) 2015-11-25
DK1267866T3 (da) 2006-10-23
AU2010200660B2 (en) 2012-04-19
JP2003530344A (ja) 2003-10-14
DE60120936T3 (de) 2016-11-17
CA2405705A1 (en) 2001-10-18
WO2001076575A3 (en) 2002-03-28
HU230958B1 (hu) 2019-06-28
DK1267866T4 (en) 2016-10-03
WO2001076575A2 (en) 2001-10-18
US7368104B2 (en) 2008-05-06
HK1050846A1 (en) 2003-07-11
NO2015025I1 (no) 2015-12-07
AU8930601A (en) 2001-10-23
LU92393I2 (fr) 2015-11-02
LU92166I2 (fr) 2014-03-13
DE60120936T2 (de) 2006-11-02
MXPA02009718A (es) 2003-05-27
ES2266242T5 (es) 2016-10-04
ES2687751T3 (es) 2018-10-29
BE2013C023I2 (de) 2020-06-24
HUP0301518A2 (hu) 2003-08-28
PT1267866E (pt) 2006-10-31
ZA200207420B (en) 2003-09-16
HUS1900056I1 (hu) 2020-02-28
NO20024708D0 (no) 2002-10-01
NO20024708L (no) 2002-10-24
HK1050846B (en) 2007-01-26
CA2405705C (en) 2011-06-07
IL151791A (en) 2015-05-31
NO2015024I2 (no) 2015-11-25
ES2266242T3 (es) 2007-03-01
EP2193791A1 (de) 2010-06-09
AU2004242450A1 (en) 2005-01-20
EP1267866B2 (de) 2016-07-20
CN1422154A (zh) 2003-06-04
BR0109875A (pt) 2004-07-20
CN1720995A (zh) 2006-01-18
PL364024A1 (en) 2004-11-29
CN1292745C (zh) 2007-01-03
IL151791A0 (en) 2003-04-10
US20080220073A1 (en) 2008-09-11
AU2010200660A1 (en) 2010-03-11
AU2004242450B2 (en) 2010-06-03
EP1449528B1 (de) 2018-08-08
DE60120936D1 (de) 2006-08-03
CN101181263B (zh) 2011-07-06

Similar Documents

Publication Publication Date Title
ATE330585T2 (de) Behandlung von atemerkrankungen
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
MXPA02011311A (es) Composicion novedosa.
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
CL2003002746A1 (es) Compuesto derivado de piridazin-3(2h)-ona sustituida en las posiciones 4,5,6; procedimiento de preparacion de dicho compuesto; compuesto intermediario; composicion farmaceutica; y el uso del compuesto para el tratamiento del asma, enfermedad pulmonar
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
BRPI0409109A (pt) novos compostos
ATE381535T1 (de) Phenethanolaminderivate
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
EA200401114A3 (ru) Замещённые гидроксиэтиламины
EA200300152A1 (ru) Фармацевтический препарат сальметерола и пропионата флутиказона
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
HRP20100208T8 (hr) Postupak liječenja akutnog rinosinusitisa
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
MEP39708A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1267866

Country of ref document: EP